- Case report
- Open Access
Efficacy of hormonal suppression in a patient with chyluria due to lymphangioleiomyomatosis
© Novamedia srl 2011
- Received: 1 July 2011
- Accepted: 19 September 2011
- Published: 31 October 2011
Lymphangioleiomyomatosis (LAM) is a rare lung disease affecting almost exclusively young women, characterised by abnormal proliferation of atypical smooth muscle cells. We describe a young woman presenting with chyluria secondary to the presence of a large retroperitoneal lymphangioleiomyoma. Immunohistochemical analysis revealed HMB45-negative LAM cells (HMB45 staining is absent only in rare cases) expressing low levels of estrogen receptors. Estrogen suppressive treatment with triptoreline, a synthetic analogue of Gn-RH, resulted in dramatic reduction of the retroperitoneal mass size. The role of estrogens in the pathogenesis of LAM remains poorly understood, and hormonal therapy is still debated, but this case suggests that at least in some LAM patients, possibly those with HMB45-negative disease and estrogen receptor expression, hormonal therapy may be effective in controlling the disease process.
Efficacia della soppressione ormonale in una paziente con chiluria secondaria a linfangioleiomiomatosi
La linfangioleiomiomatosi (LAM) è una rara patologia polmonare che colpisce quasi esclusivamente donne giovani, caratterizzata da un’anomala proliferazione di cellule muscolari lisce atipiche. Descriviamo il caso di una giovane donna presentatasi con chiluria secondaria alla presenza di un vasto linfangioleiomioma retroperitoneale. L’immunoistochimica rivelava LAM-cells negative per l’HMB45 e bassi livelli di recettori estrogenici.
Il trattamento di soppressione estrogenica con triptorelina, un analogo sintetico del GnRH ha determinato una notevole riduzione della massa retroperitoneale. Il ruolo degli estrogeni nella patogenesi della LAM non è stato ancora completamente chiarito e la terapia ormonale è ancora dibattuta, ma questo caso suggerisce che, almeno in alcune pazienti con LAM cells HMB45-negative e con espressione dei recettori per estrogeni, la terapia ormonale può essere efficace nel controllare la patologia.
Lymphangioleiomyomatosis (LAM) is a rare, progressive, frequently fatal lung disease. It affects almost exclusively pre-menopausal women and is exacerbated by pregnancy and exogenous estrogens, thus suggesting a role for estrogens in its etiology and pathology. LAM is predominantly sporadic, owing to somatic mutations in tuberous sclerosis genes, but it may also manifest in the context of tuberous sclerosis complex (TSC), an autosomal dominant disorder of highly variable penetrance [1, 2]. The pathologic hallmark of LAM is the abnormal and potentially metastatic growth of atypical smooth muscle (SM)-like cells (LAM cells) within the lungs and axial lymphatics. LAM cells typically express the melanoma-related antigen HMB-45 .
In the lung, the typical lesions are thin-walled parenchymal cysts, which cause destruction of the interstitium and progressive air-flow obstruction . In addition to the lung cysts, LAM is also characterized by renal or abdominal angiomyolipomas, perivascular tumors consisting of a mixture of LAM cells, fat cells and blood vessels . A recent report including both patients with TSC and sporadic LAM showed that sirolimus monotherapy reduced angiomyolipoma volume by nearly 50%. Conversely, improvements in airflow and gas trapping were limited to patients with LAM . However, the rate of adverse effects was high, and only a small number of patients had renal and pulmonary benefits that persisted after the drug was stopped. Another recent report  shows that treatment with sirolimus for 1 year has beneficial effects in patients with LAM, including the stabilization of forced expiratory volume in 1 second (FEV1) and improvement in forced vital capacity (FVC), quality of life, and some func-tional performance measures. But sirolimus therapy positively affected lung function only during the treatment period and it was associated with a large number of different adverse events.
Despite these somewhat promising results, and despite the recently reported effect of hormonal manipulation , effective treatment for patients with LAM is still lacking.
Estrogens have been implicated in the pathogenesis of LAM based on a number of convincing signs of evidence, including the identification of estrogen receptors (ERs) in the context of LAM cells [9–11], and the occurrence of the disease primarily in women of childbearing age. However, hormonal modulation (using a number of different approaches) has failed to provide consistent, reproducible proof of efficacy [4, 8, 12, 13]. In this regard, a recent report suggested limited efficacy of triptoreline therapy . However, in this study on 11 patients (9 of which had pathologic confirmation of their disease) no data were reported concerning the expression of estrogen receptors and HMB-45, and it is unknown whether these 9 patients represented cases of LAM in which LAMD-SM cells played a role. Importantly, ER expression has been documented in HMB-45positive, but not in HMB-45-negative LAM cells , although these data have not been confirmed.
LAM is rare so there have been no controlled trials of its management. Effective treatment for patients with LAM is still lacking and European Respiratory Society (ERS) guidelines for LAM do not have conclusive indications about effective therapeutic strategies .
Another recent report  shows that treatment with sirolimus for 1 year has beneficial effects in patients with LAM, including the stabilization of FEV1 and improvement in FVC, quality of life, and some functional performance measures. But sirolimus therapy positively affected lung function only during the treatment period and it was associated with a large number of different adverse events.
Here we report the identification of LAM cells negative for HMB-45 and expressing very low levels of ERs in a young woman with a retroperitoneal mass and lung cysts. The LAM cells found in our patient closely resemble the spindle-shaped (LAMD-SM) cells. Both in the lung specimens and in the retroperitoneal mass ER levels were almost undetectable. Similarly, Glassberg and colleagues reported that the amounts of ER-α and ER-β protein were lower in LAM tissue and LAMD-SM cell lines compared to control lung tissue and cell lines . In this regard, it has been demonstrated that unbound ERs undergo a rapid proteosome degradation in LAMD-SM cells [16, 17]. However, despite very low ER protein levels, LAMD-SM are more responsive to estrogens compared to control cells. This is not surprising, because estrogen sensitivity and responsiveness only partially depend on the levels of functional ERs . In turn, the estrogen-ER interaction drives matrix metalloproteinase (MMP)-2 and -9 synthesis and activation in LAMD-SM, thus leading to tissue invasion and destruction . HMB-45negative spindle cells have been shown to possess a high proliferating-cell nuclear antigen expression and have been implicated in the progression of LAM . The HMB-45-negative LAM cell occurrence is rare and we hypothesize that HMB-45negative LAM may represent a distinct disease phenotype, more aggressive but highly responsive to hormonal therapy. In the case reported here, the pharmacologic suppression of estrogen levels rapidly reduced the size of a large retroperitoneal mass, with consequent relief of urinary symptoms, and stabilized the extension of the pulmonary cysts. We therefore consider this case as indirect in vivo evidence in support of the so-called "estrogen hypothesis" in LAM. The fact that pregnancy and use of oral contraceptives are associated with a higher frequency of exacerbations and a more aggressive disease course, along with reports of LAM in postmenopausal women taking hormone replacement, reinforce this theory [20–22]. The patient described here displayed other peculiar features meriting further discussion. Chyluria was the presenting symptom and we hypothesize that the presence of a fistulous connection between the urinary system and the retroperitoneal lymphatic system might have been responsible for this unusual presentation of LAM. Interestingly, chyluria completely disappeared after hormonal treatment, due to the dramatic reduction in size of the retroperitoneal mass. In this patient the early occurrence of such an atypical urinary presentation prompted adequate treatment that might have been able to stop disease progression at a time when pulmonary function was only mildly impaired, but after confirmation of LAM cells in the lung tissue. Taken together, these findings underscore the importance of a high diagnostic suspicion of LAM in young women presenting with atypical clinical manifestations.
The role of estrogens in the pathogenesis of LAM remains poorly understood, and hormonal therapy (based on the antagonism of estrogen effects) is empiric and unproven. Nevertheless, our in vivo findings, coupled with recent evidence of limited efficacy of other therapeutic options, strongly suggest that hormonal therapy may still hold promise at least in some LAM patients.
None of the authors has any conflict of interest to declare in relation to the subject matter of this manuscript.
We would like to thank Jan-Åke Gustafsson, Margaret Warner and Paloma Alonso Magdalena (Karolinska Institutet, Stockholm, Sweden) for the ER staining.
- Taveira-DaSilva AM, Steagall WK, Moss J: Lymphangioleiomyomatosis. Cancer Control. 2006, 13: 276-285.PubMedGoogle Scholar
- Schiavina M, Contini P, Guerrieri A, Tavalazzi F, Fabiani A: Lymphangioleiomyomatosis: a rare disease. Multidiscip Resp Med. 2009, 4: 203-207.Google Scholar
- Tanaka H, Imada A, Morikawa T, Shibusa T, Satoh M, Sekine K, Abe S: Diagnosis of pulmonary lymphangioleiomyomatosis by HMB45 in surgically treated spontaneous pneumothorax. Eur Respir J. 1995, 8: 1879-1882. 10.1183/09031936.95.08111879.View ArticlePubMedGoogle Scholar
- Johnson SR: Lymphangioleiomyomatosis. Eur Respir J. 2006, 27: 1056-1065.PubMedGoogle Scholar
- Krymskaya VP: Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis. Proc Am Thorac Soc. 2008, 5: 119-126. 10.1513/pats.200705-061VS.PubMed CentralView ArticlePubMedGoogle Scholar
- Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008, 358: 140-151. 10.1056/NEJMoa063564.PubMed CentralView ArticlePubMedGoogle Scholar
- McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC, National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group: Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011, 364: 1595-1606. 10.1056/NEJMoa1100391.PubMed CentralView ArticlePubMedGoogle Scholar
- Schiavina M, Contini P, Fabiani A, Cinelli F, Di Scioscio V, Zompatori M, Campidelli C, Pileri SA: Efficacy of hormonal manipulation in lymphangioleiomyomatosis. A 20-year experience in 36 patients. Sarcoidosis Vasc Diffuse Lung Dis. 2007, 24: 39-50.PubMedGoogle Scholar
- Matsui K, Takeda K, Yu ZX, Valencia J, Travis WD, Moss J, Ferrans VJ: Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy. An immunohistochemical study. Am J Respir Crit Care Med. 2000, 161 (3 Pt 1): 1002-1009.View ArticlePubMedGoogle Scholar
- Berger U, Khaghani A, Pomerance A, Yacoub MH, Coombes RC: Pulmonary lymphangioleiomyomatosis and steroid receptors. An immunocytochemical study. Am J Clin Pathol. 1990, 93: 609-614.PubMedGoogle Scholar
- Glassberg MK, Elliot SJ, Fritz J, Catanuto P, Potier M, Donahue R, Stetler-Stevenson W, Karl M: Activation of the estrogen receptor contributes to the progression of pulmonary lymphangioleiomyomatosis via matrix metalloproteinase-induced cell invasiveness. J Clin Endocrinol Metab. 2008, 93: 1625-1633. 10.1210/jc.2007-1283.View ArticlePubMedGoogle Scholar
- Tomasian A, Greenberg MS, Rumerman H: Tamoxifen for lymphangioleiomyomatosis. N Engl J Med. 1982, 306: 745-746.View ArticlePubMedGoogle Scholar
- Glassberg MK: Lymphangioleiomyomatosis. Clin Chest Med. 2004, 25: 573-82. 10.1016/j.ccm.2004.05.003. viiView ArticlePubMedGoogle Scholar
- Harari S, Cassandro R, Chiodini J, Taveira-DaSilva AM, Moss J: Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis. Chest. 2008, 133: 448-454. 10.1378/chest.07-2277.PubMed CentralView ArticlePubMedGoogle Scholar
- Johnson SR, Cordier JF, Lazor R, Cottin V, Costabel U, Harari S, Reynaud-Gaubert M, Boehler A, Brauner M, Popper H, Bonetti F, Kingswood C: Review Panel of the ERS LAM Task Force. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010, 35: 14-26. 10.1183/09031936.00076209.View ArticlePubMedGoogle Scholar
- Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW: Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA. 1999, 96: 1858-1862. 10.1073/pnas.96.5.1858.PubMed CentralView ArticlePubMedGoogle Scholar
- Petrel TA, Brueggemeier RW: Increased proteasome-dependent degradation of estrogen receptor-alpha by TGF-beta1 in breast cancer cell lines. J Cell Biochem. 2003, 88: 181-190. 10.1002/jcb.10353.PubMed CentralView ArticlePubMedGoogle Scholar
- Webb P, Lopez GN, Greene GL, Baxter JD, Kushner PJ: The limits of the cellular capacity to mediate an estrogen response. Mol Endocrinol. 1992, 6: 157-167. 10.1210/me.6.2.157.PubMedGoogle Scholar
- Jaiswal VR, Baird J, Fleming J, Miller DS, Sharma S, Molberg K: Localized retroperitoneal lymphangioleiomyomatosis mimicking malignancy. A case report and review of the literature. Arch Pathol Lab Med. 2003, 127: 879-882.PubMedGoogle Scholar
- Ryu JH, Moss J, Beck GI, Lee JC, Brown KK, Chapman JT, Finlay GA, Olson EJ, Ruoss SJ, Maurer JR, Raffin TA, Peavy HH, McCarthy K, Taveira-Dasilva A, McCormack FX, Avila NA, Decastro RM, Jacobs SS, Stylianou M, Fanburg BL: The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med. 2006, 173: 105-111. 10.1164/rccm.200409-1298OC.PubMed CentralView ArticlePubMedGoogle Scholar
- Brunelli A, Catalini G, Fianchini A: Pregnancy exacerbating unsuspected mediastinal lymphangioleiomyomatosis and chylothorax. Int J Gynaecol Obstet. 1996, 52: 289-290. 10.1016/0020-7292(95)02619-3.View ArticlePubMedGoogle Scholar
- Yano S: Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous oestrogen used for infertility treatment. Thorax. 2002, 57: 1085-1086. 10.1136/thorax.57.12.1085.PubMed CentralView ArticlePubMedGoogle Scholar